by Ben Snipe | Feb 13, 2026 | UK
Alison joined Schlich as a Legal Secretary in November 2025 having established her administrative / organisational skills over 19 years in the Medical Communication industry. During her time working in the Medical Communication industry, Alison worked her way up from...
by Sean Hutchinson | Feb 10, 2026 | EPO
Background The Enlarged Board of Appeal’s decision in G 1/23 caused a significant change in practice at the European Patent Office (“EPO”), resulting in a product made publicly available before the priority date which the skilled person could not have reproduced now...
by Sean Hutchinson | Feb 5, 2026 | US & International
In many countries, patents are granted for inventions and last for 20 years, subject to payment of renewal fees at regular intervals. However, some countries permit the patent term to be extended provided certain requirements are met. In the UK and the EU, a...
by Sean Hughes | Jan 28, 2026 | US & International
At its core, the decision reinforces a stringent US approach to patent sufficiency: if a patent specification does not clearly support and enable the full scope of the claims at the priority date, those claims are vulnerable, no matter how valuable the underlying...
by Chloe Sullivan | Jan 20, 2026 | UPC
To briefly recap the key events leading up to this decision, the US Supreme Court found a lack of enablement when assessing the PCSK9 antibody claims in Amgen’s US patent and the Munich Central Division of the UPC initially revoked the European equivalent based on...
by Luke Pettit | Jan 15, 2026 | UPC
Background The UPC Court of Appeal’s decision in Otec v. Steros provides an interesting insight into claim interpretation and the constraints on relying on post-filing experimental evidence at the UPC. The case, UPC Court of Appeal decision 579/2025, arose from a...
Recent Comments